Pacira BioSciences Shares Rise Over 44% Following Acquisition by Viatris
Shares of Pacira BioSciences (PCRX) surged more than 44% on Thursday after it was announced that Viatris has agreed to acquire the biopharmaceutical company for $36.50 per share in cash. The deal values Pacira at a significant premium, reflecting confidence in its portfolio focused on non-opioid pain management solutions. Pacira BioSciences is known for developing and commercializing long-acting local anesthetics used to manage postoperative pain without opioids. Viatris' acquisition of the company aligns with broader industry trends toward diversifying therapeutic options while addressing public health concerns around opioid use.
